Recipharm signs manufacturing agreement with Enzymatica
Recipharm, a leading contract development and manufacturing organisation (CDMO) and Enzymatica, a Swedish life science company specialising in products with a protective barrier, have signed a broadened contract for the manufacture of ColdZyme®.
The agreement will involve an additional Recipharm production site in Pianezza, Italy, to support Enzymatica in increasing production volumes of ColdZyme to meet growing global demand. Both the facilities in Parets, Spain, and Pianezza, Italy, will be making additional investments to accommodate requirements moving forward.
Kenth Berg, Vice President Business Management at Recipharm said “Signing this expanded agreement is a great example of the long-term partnerships we build with our customers. Not only are we committed to providing high quality services and ensuring we meet project requirements, but we invest to adapt in line with our customers’ needs. This really is a testimony to the strength of our relationship with Enzymatica.”
“Recipharm’s strong track record, extensive expertise in managing the development and manufacturing complexities of combined drug and device products, are part of the reason we have enjoyed such a successful partnership to date. We are confident as we move forward, we can continue to provide the high levels of expertise, regulatory experience, quality and resource to support Enzymatica as they continue to grow.”
Claus Egstrand, Chief Operating Officer at Enzymatica said “We’re delighted to have signed this contract with Recipharm. The team’s ability to support us with the production of our products for various markets has been invaluable and we’re confident they’re the right partner for us as we continue to grow on a global scale.”
ColdZyme is one of Enzymatica’s first products and is intended to treat and alleviate common cold. The product has already been launched in about 30 countries across three continents.
Kenth Berg, Vice President Business Management Recipharm, firstname.lastname@example.org, +46 8 6025 216
Claus Egstrand, Chief Operating Officer Enzymatica, Claus.Egstrand@enzymatica.com, +46 46 286 31 00
For media enquiries, please contact Kate Hindhaugh at ramarketing: email@example.com, +44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about 30 markets on 3 continents. The strategy is to continue to grow by developing more health care products and strengthening the company’s position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market.
For more information, visit: www.enzymatica.se